98%
921
2 minutes
20
Background And Objectives: Status epilepticus (SE) is associated with high short-term mortality, but data on long-term outcomes, including recurrence and mortality, are limited. The aim of this study was to describe recurrence and postdischarge mortality rates up to 3 years after an initial SE and identify the associated risk factors.
Methods: We conducted a retrospective cohort study involving all patients, infants and adults, who survived their first hospitalization with an ICD-10 code of SE from January 1, 2011, to December 31, 2016, using the French National Health Data System, with a 3-year follow-up. Outcomes included SE recurrence, death, and cause of death from death certificates. Measures included patient characteristics, comorbidities, SE causes, intensive care unit admissions, and mechanical ventilation at the first SE. Multivariable Cox models assessed the relationships between these factors and recurrence or mortality.
Results: Among 37,930 patients (46.4% female, median age 55 years [interquartile range (IQR) 30-71]), the 3-year recurrence rate was 16.7% (95% CI 16.3-17.1) and the mortality rate was 25% (95% CI 24.5-25.4). Factors present at first SE associated with 3-year recurrence were younger age (hazard ratio [HR] 2.21, 95% CI 1.90-2.58, for age group <1 compared with 10-19 years), history of epilepsy before first SE (HR 1.73, IQR 1.63-1.84), alcohol consumption (HR 1.37, 95% CI 1.27-1.48), remote and progressive causes, comorbidities, and prolonged mechanical ventilation (HR 1.21, 95% CI 1.11-1.32). Progressive causes and higher number of comorbidities were also associated with mortality, but male sex (HR 1.24, 95% CI 1.19-1.30) and older age were specifically associated with mortality and not recurrence. Main causes of death at 3 years were tumors (32.1%), cardiovascular diseases (20.2%), and infectious or respiratory diseases (8.3%).
Discussion: Our study highlights a high risk of recurrence or death within 3 years after a first SE. We identified factors associated with increased risk of both recurrence and mortality and factors specifically associated with recurrence or mortality. A better understanding of these factors, which are mostly nonmodifiable at the time of discharge, could assist clinicians in better planning patient follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1212/WNL.0000000000213693 | DOI Listing |
Surg Infect (Larchmt)
September 2025
Department of Surgery, Division of Acute Care Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Patients with traumatic injuries who develop ventilator-associated pneumonia (VAP) incur a higher risk of developing multi-drug resistance. Shorter duration of antibiotic agents for early VAP at five days may reduce antibiotic agent exposure without worsening patient outcomes. This retrospective cohort study performed at a Level I Trauma Center included adult (≥16 years old) patients with trauma diagnosed with bronchoalveolar lavage (BAL)-proven early (within four days of intubation) bacterial VAP.
View Article and Find Full Text PDFSurg Endosc
September 2025
Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
Background: The implementation of minimally invasive liver surgery (MILS) for perihilar (PHC) and intrahepatic cholangiocarcinoma (IHC) remains limited and a systematic review including only comparative studies of MILS versus the open approach is lacking. This systematic review and meta-analysis aimed to assess the safety and efficacy of minimally invasive surgery in patients with hilar and intrahepatic cholangiocarcinomas.
Methods: Systematic review in the PubMed, Embase, and Cochrane databases for original studies comparing at least five patients undergoing MILS with open liver surgery for PHC and IHC.
BMJ Open
September 2025
Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Introduction: Nipah virus (NiV) is a bat-transmitted paramyxovirus causing recurrent, high-mortality outbreaks in South and South-East Asia. As a WHO priority pathogen, efforts are underway to develop therapies like monoclonal antibodies and small-molecule antivirals, which require evaluation in clinical trials. However, trial design is challenging due to limited understanding of NiV's clinical characteristics.
View Article and Find Full Text PDFMed Oncol
September 2025
Division of Hematology and Blood Bank, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Acute Myeloid Leukemia (AML) patient-derived Mesenchymal Stem Cells (MSCs) behave differently than normal ones, creating a more protective environment for leukemia cells, making relapse harder to prevent. This study aimed to identify prognostic biomarkers and elucidate relevant biological pathways in AML by leveraging microarray data and advanced bioinformatics techniques. We retrieved the GSE122917 dataset from the NCBI Gene Expression Omnibus and performed differential expression analysis (DEA) within R Studio to identify differentially expressed genes (DEGs) among healthy donors, newly diagnosed AML patients, and relapsed AML patients.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
HepatoBiliaryPancreatic Surgery, AOU Careggi, Department of Experimental and Clinical Medicine (DMSC), University of Florence, Florence, Italy.
Purpose: To build computed tomography (CT)-based radiomics models, with independent external validation, to predict recurrence and disease-specific mortality in patients with colorectal liver metastases (CRLM) who underwent liver resection.
Methods: 113 patients were included in this retrospective study: the internal training cohort comprised 66 patients, while the external validation cohort comprised 47. All patients underwent a CT study before surgery.